Tritum AMS Analysis of Cancer Biomarkers

Information

  • Research Project
  • 7191665
  • ApplicationId
    7191665
  • Core Project Number
    R42CA084688
  • Full Project Number
    5R42CA084688-06
  • Serial Number
    84688
  • FOA Number
    PAR-01-105
  • Sub Project Id
  • Project Start Date
    9/27/2004 - 20 years ago
  • Project End Date
    3/31/2009 - 15 years ago
  • Program Officer Name
    DASCHNER, PHILLIP J.
  • Budget Start Date
    3/1/2007 - 17 years ago
  • Budget End Date
    3/31/2009 - 15 years ago
  • Fiscal Year
    2007
  • Support Year
    6
  • Suffix
  • Award Notice Date
    2/12/2007 - 17 years ago
Organizations

Tritum AMS Analysis of Cancer Biomarkers

DESCRIPTION (provided by applicant): The goal of this Phase II STTR program is to develop a high-throughput, ultra-sensitive accelerator mass spectrometer for the detection and quantification of tritium in labeled biological molecules. Accelerator mass spectrometry (AMS) is a highly selective means for detecting tritium that can achieve a measurement sensitivity over 1000 times greater than decay counting. Existing AMS instruments capable of measuring tritium are designed to also measure 14C and other higher mass isotopes. However, significant advantages accrue to an AMS system dedicated to the measurement of tritium. One advantage is greatly reduced instrument size and cost. A second, and perhaps even more important advantage, is high sample throughput. The low natural abundance of 3H, which is more than 1000 times lower than that of 14C, means that smaller absolute quantities and concentrations of tritium can be detected in labeled samples with equal measurement accuracy. Consequently, tritium AMS can be used in conjunction with very small volume, high-throughput microfluidic sample processing systems. A unique feature of the proposed system is integration of the AMS with interfaces that permit rapid, direct introduction of discrete samples as well as continuous-flow monitoring of chromatography. The resulting design lends itself to high-throughput applications that are inaccessible to conventional AMS approaches. In Phase I we demonstrated detection of 3H-labeled solution samples at very low energy using an existing dual-isotope biomedical AMS instrument. This work has allowed us to design an AMS instrument that is truly comparable in size and cost to other major laboratory analytical instruments, but that provides the unique capabilities of AMS for detection of extremely small quantities and concentrations of 3H-labeled compounds. In Phase II, we will design, fabricate and test a dedicated 3H-AMS instrument with sample introduction interfaces for both continuous sample injection via HPLC, as well as rapid introduction of discrete samples via microfluidic technologies. The resulting integrated systems will provide dramatic improvements in sample throughput, speed of analysis, and measurement sensitivity compared with presently available analytical instruments. This program is a collaboration between Newton Scientific, Inc., and the Biological Engineering Division at the Massachusetts Institute of Technology.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R42
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    430840
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    393
  • Ed Inst. Type
  • Funding ICs
    NCI:430840\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NEWTON SCIENTIFIC, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02141
  • Organization District
    UNITED STATES